[CAS NO. 346640-08-2] CCF642
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [346640-08-2]
Catalog
SLK-S8281
Brand
Selleck
CAS
346640-08-2
DESCRIPTION [346640-08-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 378.45 |
| Molecular Formula | C15H10N2O4S3 |
| SMILES | O=C1N(C2=CC=C(OC)C=C2)C(S/C1=C/C3=CC=C([N+]([O-])=O)S3)=S |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6424 mL | 13.2118 mL | 26.4236 mL |
| 5 mM | 0.5285 mL | 2.6424 mL | 5.2847 mL |
| 10 mM | 0.2642 mL | 1.3212 mL | 2.6424 mL |
| 50 mM | - | - | - |
Description
CCF642 (AC1LYELL) is a novel compound with antimyeloma activity.
Targets
| protein disulfide isomerases [1] |
In vitro
In vitro, CCF642 inhibits PDI reductase activity about 100-fold more potently than the structurally distinct established inhibitors PACMA 31 and LOC14. Computational modeling suggests a novel covalent binding mode in active-site CGHCK motifs. CCF642 causes acute ER stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release.
In vivo
CCF642 displays potent efficacy in an aggressive syngeneic mouse model of multiple myeloma and prolongs the lifespan of C57BL/KaLwRij mice engrafted with 5TGM1-luc myeloma, an effect comparable to the first-line multiple myeloma therapeutic bortezomib.
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.